Nouvelle déclaration d'incident
No de la demande: 2018-2047
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2018-US0011722 (Report 477298)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson BLVD
Ville: Mississauga
État: ON
Pays: Canada
Code postal /Zip: L5W5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Small Dog
Autre (préciser)
COLLAROui
Autres unités: Collar
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Dog / Chien
Shih Tzu
1
Femme
14
5.851
kg
Cutanée
>1 mo <= 6 mos / > 1 mois < = 6 mois
>3 days <=1 wk / >3 jours <=1 sem
Système
>2 mos and <=6mos />2 mois et <=6mois
Oui
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 26 Jan 2018, the dog had very dark urine and lethargy. On approximately 15 Feb 2018, the dog was examined by a veterinarian and blood work was performed and reveled increased pancreatic enzymes. No treatments were performed. Clinical signs continued. On 30 Mar 2018, the dog began vomiting and had difficulty breathing. The dog was examined by a veterinarian and the dog was administered and unknown amount of subcutaneous fluids and was administered an unspecified antibiotic injection. On 31 Mar 2018, the dog had a seizure and died at home. No necropsy was performed. No more information is expected. This case is closed.
Mort
N-Unlikely: Reported dark urine is not an expected sign with appropriate topical product application. Lethargy is unspecific and may have various other causes. Reported digestive signs are unspecific and may have numerous other causes (e.g. gastrointestinal infection, dietary incompatibility). Mild gastrointestinal signs may occur shortly after product application, but here time to onset is too long. No oral product exposure reported. Difficulty in breathing is not anticipated after product administration. The product is not anticipated to cause serious neurological disorders such as seizures after appropriate topical product administration as the controlled release mechanism assures release of only low doses of active ingredient at a time. Even with oral product exposure, seizures are not expected. Merely gastrointestinal signs would be possible. Various etiologies exist for seizure events or paroxysmal signs, e.g. heart disorder, development disorder, metabolic disorder, infection, intoxication, idiopathic epilepsy, trauma, neoplasms. Death is not expected following appropriate topical product application as inconsistent with product's pharmacological profile. Oral exposure to the collar is not expected to cause serious signs either. An overdose of 5 collars around the neck was investigated in adult cats and dogs for an 8 months period and in 10 week old kittens and 7 week old puppies for a 6 months period without causing serious signs. No signs of anaphylaxis reported which would have occurred in close proximity to the collar application. Time to onset long. Other causes are more probable in this geriartric dog. Even though no necropsy is available, considering the known product profile sufficient information exists to conclude that the product did not cause the event and product involvement was ruled out.